Cargando…

Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment

Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Bhavin K., Parikh, Rajesh H., Aboti, Pooja S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759266/
https://www.ncbi.nlm.nih.gov/pubmed/24024034
http://dx.doi.org/10.1155/2013/370938
_version_ 1782477229995851776
author Patel, Bhavin K.
Parikh, Rajesh H.
Aboti, Pooja S.
author_facet Patel, Bhavin K.
Parikh, Rajesh H.
Aboti, Pooja S.
author_sort Patel, Bhavin K.
collection PubMed
description Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug moiety in the hydrophilic matrix of polymer is applied for rifampicin delivery using CN. The 2(3) full-factorial design was employed by selecting the independent variables such as Chitosan concentration (X (1)), concentration of tripolyphosphate (X (2)), and homogenization speed (X (3)) in order to achieve desired particle size with maximum percent entrapment efficiency and drug loading. The design was validated by checkpoint analysis, and formulation was optimized using the desirability function. Results. Particle size, drug entrapment efficiency, and drug loading for the optimized batch were found to be 221.9 nm, 44.17 ± 1.98% W/W, and 42.96 ± 2.91% W/W, respectively. In vitro release data of optimized formulation showed an initial burst followed by slow sustained drug release. Kinetic drug release from CNs was best fitted to Higuchi model. Conclusion. Design of Experiment is an important tool for obtaining desired characteristics of rifampicin loaded CNs. In vitro study suggests that oral sustained release CNs might be an effective drug delivery system for tuberculosis.
format Online
Article
Text
id pubmed-3759266
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37592662013-09-10 Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment Patel, Bhavin K. Parikh, Rajesh H. Aboti, Pooja S. J Drug Deliv Research Article Objective. The main objective of the present investigation was to develop and optimize oral sustained release Chitosan nanoparticles (CNs) of rifampicin by design of experiment (DOE). Methodology. CNs were prepared by modified emulsion ionic gelation technique. Here, inclusion of hydrophobic drug moiety in the hydrophilic matrix of polymer is applied for rifampicin delivery using CN. The 2(3) full-factorial design was employed by selecting the independent variables such as Chitosan concentration (X (1)), concentration of tripolyphosphate (X (2)), and homogenization speed (X (3)) in order to achieve desired particle size with maximum percent entrapment efficiency and drug loading. The design was validated by checkpoint analysis, and formulation was optimized using the desirability function. Results. Particle size, drug entrapment efficiency, and drug loading for the optimized batch were found to be 221.9 nm, 44.17 ± 1.98% W/W, and 42.96 ± 2.91% W/W, respectively. In vitro release data of optimized formulation showed an initial burst followed by slow sustained drug release. Kinetic drug release from CNs was best fitted to Higuchi model. Conclusion. Design of Experiment is an important tool for obtaining desired characteristics of rifampicin loaded CNs. In vitro study suggests that oral sustained release CNs might be an effective drug delivery system for tuberculosis. Hindawi Publishing Corporation 2013 2013-08-18 /pmc/articles/PMC3759266/ /pubmed/24024034 http://dx.doi.org/10.1155/2013/370938 Text en Copyright © 2013 Bhavin K. Patel et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Patel, Bhavin K.
Parikh, Rajesh H.
Aboti, Pooja S.
Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title_full Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title_fullStr Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title_full_unstemmed Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title_short Development of Oral Sustained Release Rifampicin Loaded Chitosan Nanoparticles by Design of Experiment
title_sort development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759266/
https://www.ncbi.nlm.nih.gov/pubmed/24024034
http://dx.doi.org/10.1155/2013/370938
work_keys_str_mv AT patelbhavink developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment
AT parikhrajeshh developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment
AT abotipoojas developmentoforalsustainedreleaserifampicinloadedchitosannanoparticlesbydesignofexperiment